Ireland· IE-PA-EU/1/17/1199/001
Cuprior 150 mg film-coated tablets
A trientine product containing trientine tetrahydrochloride, registered in Ireland by gmp-orphan SA. The same ATC class is registered in 19 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Trientine is registered in 19 of 19 countries.
Countries holding a registration under ATC A16AX12 (trientine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 11 of them publish a price we can compare per daily dose
Trientine · ATC A16AX12
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trientine costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), the median price runs from $97.54 in Switzerland to $186.45 in Italy — a ×1.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trientine · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- IT Italy$186.45
- CH Switzerland$97.54
The record
At a glance
HPRA (Ireland)- Active substance
- Trientine tetrahydrochloride
- Manufacturer
- gmp-orphan SA
- Country
- Ireland (IE)
- ATC code
- A16AX12
- ATC class
- Trientine
- Defined daily dose
- 0.45 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/17/1199/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
35 interactions on record for trientine.
Graded by severity as the source publishes them — 31 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trientine · interactions on record
35 records
- 31 moderate
- 4 minor
Most severe, free to view
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trientine in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c3b934b8-d93c-4a10-8abe-367a23d878c8 GET /v1/drugs/c3b934b8-d93c-4a10-8abe-367a23d878c8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A16AX",
"A16AX12"
],
"strength": null,
"pa_number": "EU/1/17/1199/001",
"substances": [
"Trientine tetrahydrochloride"
],
"legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "05/09/2017",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about trientine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.